LEROCHOL Approval Puts Monthly Injectable Biologics in Focus

LIB Therapeutics received FDA approval on December 12, 2025 for LEROCHOL (lerodalcibep-liga), a once-monthly subcutaneous PCSK9 inhibitor indicated to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia. For fill-finish operations and CDMOs already managing capacity constraints on injectable biologics, a monthly self-administered subcutaneous format adds a distinct set of demands around device compatibility, cold-chain integrity, and sterility assurance at commercial scale.

The FDA based its approval on data from three randomized, double-blind, placebo-controlled trials enrolling a combined 2,322 patients. Two trials (NCT04797247; NCT04806893) evaluated 1,844 adults with atherosclerotic cardiovascular disease or elevated ASCVD risk over 52 weeks. A third trial (NCT04797104) enrolled 478 patients with HeFH over 24 weeks. All three trials measured percent change in LDL-C from baseline to end of treatment against placebo. Trials were conducted across 65 sites in 11 countries, including the United States, Canada, Germany, Spain, India, New Zealand, the United Kingdom, South Africa, Norway, Israel, and Turkey. All enrolled patients were on background lipid-lowering therapy, including maximally tolerated statin doses, at the time of randomization.

The once-monthly subcutaneous dosing interval distinguishes LEROCHOL from earlier PCSK9 inhibitors dosed biweekly, a factor with direct implications for patient adherence programs and for manufacturers sizing batch release cycles and stability testing protocols under ICH Q10 and 21 CFR Part 211 frameworks. QA and regulatory affairs teams at sites handling similar biologic formats should anticipate comparability questions if technology transfers or secondary manufacturing arrangements are pursued as commercial volumes scale.

Source: FDA Drug Trials Snapshots: LEROCHOL, published April 28, 2026. Refer to the full LEROCHOL Prescribing Information for approved indications, populations, dosing, and safety information.